Trial Profile
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Nov 2022
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Vactosertib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2022 Planned End Date changed from 30 Dec 2020 to 30 Dec 2023.
- 13 Jun 2022 Planned primary completion date changed from 14 Sep 2020 to 1 Dec 2022.
- 07 Jun 2022 Results (n=16)presented at the 58th Annual Meeting of the American Society of Clinical Oncology